NI201200072A - Métodos y composiciones para tratar cáncer - Google Patents
Métodos y composiciones para tratar cáncerInfo
- Publication number
- NI201200072A NI201200072A NI201200072A NI201200072A NI201200072A NI 201200072 A NI201200072 A NI 201200072A NI 201200072 A NI201200072 A NI 201200072A NI 201200072 A NI201200072 A NI 201200072A NI 201200072 A NI201200072 A NI 201200072A
- Authority
- NI
- Nicaragua
- Prior art keywords
- treat cancer
- methods
- compositions
- methyl
- ylethynyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención presenta métodos, equipos y composiciones farmacéuticas para tratar cáncer, utilizando 3 - ( imidazo [1, 2 - b] piridazin - 3 - iletinil) - 4 - metil - N - (( 4 - metilpiperazin - 1 - il ) - metil ) - 3 - ( trifluorometil) fenil) benzamida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25666909P | 2009-10-30 | 2009-10-30 | |
US25669009P | 2009-10-30 | 2009-10-30 | |
US26101409P | 2009-11-13 | 2009-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201200072A true NI201200072A (es) | 2012-08-20 |
Family
ID=43922622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201200072A NI201200072A (es) | 2009-10-30 | 2012-04-27 | Métodos y composiciones para tratar cáncer |
Country Status (15)
Country | Link |
---|---|
US (2) | US20120316137A1 (es) |
EP (2) | EP2493460A4 (es) |
JP (1) | JP2013509444A (es) |
KR (1) | KR20120115237A (es) |
CN (1) | CN102770129A (es) |
AU (1) | AU2010313152A1 (es) |
CA (1) | CA2777128A1 (es) |
CL (1) | CL2012001133A1 (es) |
CR (1) | CR20120202A (es) |
EA (1) | EA201290255A1 (es) |
IL (1) | IL218987A0 (es) |
MX (1) | MX2012005023A (es) |
NI (1) | NI201200072A (es) |
WO (1) | WO2011053938A1 (es) |
ZA (1) | ZA201202256B (es) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007075869A2 (en) | 2005-12-23 | 2007-07-05 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
EP2793893A4 (en) * | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
CN103570724B (zh) * | 2012-07-27 | 2015-12-16 | 中国科学院广州生物医药与健康研究院 | ponatinib 的合成方法 |
US10172796B2 (en) | 2012-12-03 | 2019-01-08 | Manli International Ltd. | Use of umirolimus and its derivatives for treating cancer |
CA3022250A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
AU2013204506B2 (en) * | 2012-12-13 | 2016-05-05 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
EP2964260A2 (en) | 2013-03-06 | 2016-01-13 | F. Hoffmann-La Roche AG | Methods of treating and preventing cancer drug resistance |
US20140343282A1 (en) | 2013-05-16 | 2014-11-20 | Apicore, Llc | Processes for making ponatinib and intermediates thereof |
WO2015001098A1 (en) * | 2013-07-04 | 2015-01-08 | Sandoz Ag | Crystalline forms of ponatinib hydrochloride |
EP3027211B1 (en) * | 2013-07-30 | 2017-11-01 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch for the treatment of hematological neoplasms |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085972A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE |
WO2015085971A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Hydrobromide salt of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide |
WO2015085973A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt |
PL3087051T3 (pl) | 2013-12-24 | 2021-02-22 | Oncotartis Inc. | Związki benzamidowe i nikotynamidowe oraz sposoby ich stosowania |
CN104496995A (zh) * | 2014-01-06 | 2015-04-08 | 广东东阳光药业有限公司 | 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法 |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
CN105267200A (zh) * | 2014-07-01 | 2016-01-27 | 中国科学院上海有机化学研究所 | 一种黄酮类化合物的应用 |
US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
JP6807385B2 (ja) | 2015-11-02 | 2021-01-06 | ブループリント メディシンズ コーポレイション | Retの阻害剤 |
UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
CN106236732A (zh) * | 2016-08-31 | 2016-12-21 | 佛山市弘泰药物研发有限公司 | 一种依维莫司软胶囊的制备方法 |
KR20190092538A (ko) * | 2016-12-15 | 2019-08-07 | 어리어드 파마슈티칼스, 인코포레이티드 | C-kit 억제제로서의 벤즈이미다졸 화합물 |
CN108047230B (zh) * | 2017-12-29 | 2020-04-17 | 深圳蓝新科技有限公司 | 帕纳替尼的制备方法 |
CA3096043A1 (en) | 2018-04-03 | 2019-10-10 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
CN109875999B (zh) * | 2018-05-29 | 2022-07-12 | 上海交通大学医学院附属第九人民医院 | 泊那替尼在kit突变型恶性黑色素瘤中的应用 |
EP3781568A1 (en) | 2018-06-22 | 2021-02-24 | Johnson Matthey Public Limited Company | Form of ponatinib |
US20220296587A1 (en) * | 2019-12-09 | 2022-09-22 | Ascentage Pharma (Suzhou | Pharmaceutical composition containing alkynyl compound and preparation method and application thereof |
US20230183810A1 (en) * | 2020-05-04 | 2023-06-15 | Dna-Seq, Inc. | Methods and systems for determination of an effective therapeutic regimen and drug discovery |
WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
CN114796227B (zh) * | 2022-05-30 | 2023-12-01 | 中山大学 | Ponatinib在制备预防或治疗血管退行性疾病药物中的应用及该药物 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US4316885A (en) | 1980-08-25 | 1982-02-23 | Ayerst, Mckenna And Harrison, Inc. | Acyl derivatives of rapamycin |
US4650803A (en) | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
US5023264A (en) | 1990-07-16 | 1991-06-11 | American Home Products Corporation | Rapamycin oximes |
US5023263A (en) | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5221670A (en) | 1990-09-19 | 1993-06-22 | American Home Products Corporation | Rapamycin esters |
US5233036A (en) | 1990-10-16 | 1993-08-03 | American Home Products Corporation | Rapamycin alkoxyesters |
US5120842A (en) | 1991-04-01 | 1992-06-09 | American Home Products Corporation | Silyl ethers of rapamycin |
US5100883A (en) | 1991-04-08 | 1992-03-31 | American Home Products Corporation | Fluorinated esters of rapamycin |
US5118678A (en) | 1991-04-17 | 1992-06-02 | American Home Products Corporation | Carbamates of rapamycin |
US5118677A (en) | 1991-05-20 | 1992-06-02 | American Home Products Corporation | Amide esters of rapamycin |
US5162333A (en) | 1991-09-11 | 1992-11-10 | American Home Products Corporation | Aminodiesters of rapamycin |
US5177203A (en) | 1992-03-05 | 1993-01-05 | American Home Products Corporation | Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents |
GB9221220D0 (en) | 1992-10-09 | 1992-11-25 | Sandoz Ag | Organic componds |
US5434260A (en) | 1992-10-13 | 1995-07-18 | American Home Products Corporation | Carbamates of rapamycin |
US5489680A (en) | 1992-10-13 | 1996-02-06 | American Home Products Corporation | Carbamates of rapamycin |
US5480989A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5302584A (en) | 1992-10-13 | 1994-04-12 | American Home Products Corporation | Carbamates of rapamycin |
US5480988A (en) | 1992-10-13 | 1996-01-02 | American Home Products Corporation | Carbamates of rapamycin |
US5411967A (en) | 1992-10-13 | 1995-05-02 | American Home Products Corporation | Carbamates of rapamycin |
US5262423A (en) | 1992-10-29 | 1993-11-16 | American Home Products Corporation | Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents |
US5258389A (en) | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
US5504091A (en) | 1993-04-23 | 1996-04-02 | American Home Products Corporation | Biotin esters of rapamycin |
US5373014A (en) | 1993-10-08 | 1994-12-13 | American Home Products Corporation | Rapamycin oximes |
US5391730A (en) | 1993-10-08 | 1995-02-21 | American Home Products Corporation | Phosphorylcarbamates of rapamycin and oxime derivatives thereof |
US5378836A (en) | 1993-10-08 | 1995-01-03 | American Home Products Corporation | Rapamycin oximes and hydrazones |
US5385910A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Gem-distributed esters of rapamycin |
US5385909A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Heterocyclic esters of rapamycin |
US5385908A (en) | 1993-11-22 | 1995-01-31 | American Home Products Corporation | Hindered esters of rapamycin |
US5389639A (en) | 1993-12-29 | 1995-02-14 | American Home Products Company | Amino alkanoic esters of rapamycin |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5463048A (en) | 1994-06-14 | 1995-10-31 | American Home Products Corporation | Rapamycin amidino carbamates |
US5491231A (en) | 1994-11-28 | 1996-02-13 | American Home Products Corporation | Hindered N-oxide esters of rapamycin |
US5563145A (en) | 1994-12-07 | 1996-10-08 | American Home Products Corporation | Rapamycin 42-oximes and hydroxylamines |
US5780462A (en) | 1995-12-27 | 1998-07-14 | American Home Products Corporation | Water soluble rapamycin esters |
WO1998002441A2 (en) | 1996-07-12 | 1998-01-22 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
TW557297B (en) | 1997-09-26 | 2003-10-11 | Abbott Lab | Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same |
JP2000119181A (ja) | 1998-10-06 | 2000-04-25 | Kureha Chem Ind Co Ltd | エスクレチン及びその誘導体の放出制御経口製剤 |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
US20030220297A1 (en) | 2002-02-01 | 2003-11-27 | Berstein David L. | Phosphorus-containing compounds and uses thereof |
US20050026868A1 (en) | 2003-07-11 | 2005-02-03 | Metcalf Chester A. | Phosphorus-containing macrocycles |
GB0229022D0 (en) * | 2002-12-12 | 2003-01-15 | Novartis Ag | Organic Compounds |
JPWO2005063720A1 (ja) * | 2003-12-25 | 2007-07-19 | 日本新薬株式会社 | アミド誘導体及び医薬 |
GB0512324D0 (en) * | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
GB0417905D0 (en) * | 2004-08-11 | 2004-09-15 | Novartis Ag | Organic compounds |
KR20070113252A (ko) | 2005-02-25 | 2007-11-28 | 쿠도스 파마슈티칼스 리미티드 | 2,4-디아미노-피리도피리미딘 유도체 및 이의 mTOR억제제로서의 용도 |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
SI1973545T1 (sl) * | 2005-12-23 | 2013-04-30 | Ariad Pharmaceuticals, Inc. | Spojine bicikličnega heteroarila |
WO2007075869A2 (en) | 2005-12-23 | 2007-07-05 | Ariad Pharmaceuticals, Inc. | Bicyclic heteroaryl compounds |
EP1979325A1 (en) | 2006-01-11 | 2008-10-15 | AstraZeneca AB | Morpholino pyrimidine derivatives and their use in therapy |
EP2007391B8 (en) * | 2006-04-07 | 2013-05-29 | Novartis AG | Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315ile kinase inhibitor |
EP2016075A1 (en) | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
EP2029593A1 (en) | 2006-05-22 | 2009-03-04 | AstraZeneca AB | Indole derivatives |
WO2008023180A1 (en) | 2006-08-24 | 2008-02-28 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
KR101435231B1 (ko) | 2006-08-24 | 2014-10-02 | 아스트라제네카 아베 | 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체 |
WO2008032060A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperazinylpyrimidine derivatives as p13k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032091A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-6-m0rph0lin0-2-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032036A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 6-benzimidaz0lyl-2-m0rph0lin0-4- (azetidine, pyrrolidine, piperidine or azepine) pyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032077A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives |
WO2008032041A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | Pyrimidine derivatives having inhibitory activity against pi3k enzymes |
US20090270390A1 (en) | 2006-09-14 | 2009-10-29 | Astrazeneca | Pyrimidine derivatives |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008032089A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidaz0lyl-2-m0rph0lin0-6-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
US20090105270A1 (en) * | 2007-02-20 | 2009-04-23 | Buser-Doepner Carolyn A | Kinase inhibition and anticancer therapy |
JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | mTORC1及びmTORC2の両方の阻害剤を含む組み合わせ抗癌療法 |
AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
JP2010533159A (ja) | 2007-07-09 | 2010-10-21 | アストラゼネカ アクチボラグ | 化合物947 |
WO2009007751A2 (en) | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
CN101809002B (zh) | 2007-07-09 | 2013-03-27 | 阿斯利康(瑞典)有限公司 | 用于与mtor激酶和/或pi3k相关的疾病中的吗啉代嘧啶衍生物 |
WO2009076373A1 (en) * | 2007-12-10 | 2009-06-18 | Concert Pharmaceuticals Inc. | Heterocyclic kinase inhibitors |
EP2611443A2 (en) * | 2010-09-01 | 2013-07-10 | ArQule, Inc. | Methods for treatment of non-small cell lung cancer |
-
2010
- 2010-11-01 EP EP10827625.4A patent/EP2493460A4/en not_active Withdrawn
- 2010-11-01 AU AU2010313152A patent/AU2010313152A1/en not_active Abandoned
- 2010-11-01 EA EA201290255A patent/EA201290255A1/ru unknown
- 2010-11-01 CN CN2010800491501A patent/CN102770129A/zh active Pending
- 2010-11-01 WO PCT/US2010/055016 patent/WO2011053938A1/en active Application Filing
- 2010-11-01 CA CA2777128A patent/CA2777128A1/en not_active Abandoned
- 2010-11-01 JP JP2012537178A patent/JP2013509444A/ja active Pending
- 2010-11-01 MX MX2012005023A patent/MX2012005023A/es not_active Application Discontinuation
- 2010-11-01 EP EP13189355.4A patent/EP2762142A1/en not_active Withdrawn
- 2010-11-01 US US13/504,251 patent/US20120316137A1/en not_active Abandoned
- 2010-11-01 KR KR1020127014086A patent/KR20120115237A/ko not_active Application Discontinuation
-
2012
- 2012-03-28 ZA ZA2012/02256A patent/ZA201202256B/en unknown
- 2012-04-02 IL IL218987A patent/IL218987A0/en unknown
- 2012-04-25 CR CR20120202A patent/CR20120202A/es unknown
- 2012-04-27 NI NI201200072A patent/NI201200072A/es unknown
- 2012-04-30 CL CL2012001133A patent/CL2012001133A1/es unknown
-
2013
- 2013-03-13 US US13/802,039 patent/US20130178622A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2012005023A (es) | 2012-06-19 |
EP2762142A1 (en) | 2014-08-06 |
IL218987A0 (en) | 2012-06-28 |
CL2012001133A1 (es) | 2013-08-02 |
KR20120115237A (ko) | 2012-10-17 |
JP2013509444A (ja) | 2013-03-14 |
ZA201202256B (en) | 2012-12-27 |
EP2493460A1 (en) | 2012-09-05 |
WO2011053938A8 (en) | 2011-08-11 |
EA201290255A1 (ru) | 2013-04-30 |
CA2777128A1 (en) | 2011-05-05 |
CN102770129A (zh) | 2012-11-07 |
WO2011053938A1 (en) | 2011-05-05 |
US20120316137A1 (en) | 2012-12-13 |
US20130178622A1 (en) | 2013-07-11 |
AU2010313152A1 (en) | 2012-04-19 |
CR20120202A (es) | 2012-06-12 |
EP2493460A4 (en) | 2013-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201200072A (es) | Métodos y composiciones para tratar cáncer | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
DOP2015000304A (es) | Inhibidores cristalinos de bromodominios | |
EA201000774A1 (ru) | Ингибиторы бета-лактамазы | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
DOP2010000134A (es) | Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos | |
EA201170521A1 (ru) | Новые соединения | |
EA200901486A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
MX2012001974A (es) | Compuestos de biarilo y metodos de uso de los mismos. | |
EA201270722A1 (ru) | Формы рифаксимина и их применение | |
UA112425C2 (uk) | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ | |
MY154898A (en) | P70 s6 kinase inhibitors | |
EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
PH12015501609A1 (en) | Phenicol antibacterials | |
MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
ATE530170T1 (de) | Paliperidonformulierung mit verzögerter freisetzung | |
BRPI0911577A8 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. | |
TW200942524A (en) | Novel aminomethyl benzene derivatives | |
EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы | |
WO2011150201A3 (en) | Azolyl amide compounds and methods of use thereof | |
HK1142608A1 (en) | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof 5- | |
WO2014093583A3 (en) | Synthetic methods for preparing 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride, other salt forms of this compound and intermediates thereof | |
EA200901484A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR |